Compare ASTRAZENECA PHARMA with IPCA Labs - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs IPCA LABS - Comparison Results

ASTRAZENECA PHARMA     Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

IPCA LABS 
   Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA IPCA LABS ASTRAZENECA PHARMA/
IPCA LABS
 
P/E (TTM) x 115.3 37.8 305.0% View Chart
P/BV x 33.7 7.9 426.8% View Chart
Dividend Yield % 0.0 0.2 -  

Financials

 ASTRAZENECA PHARMA   IPCA LABS
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-18
IPCA LABS
Mar-19
ASTRAZENECA PHARMA/
IPCA LABS
5-Yr Chart
Click to enlarge
High Rs1,2781,042 122.6%   
Low Rs883590 149.6%   
Sales per share (Unadj.) Rs228.4298.6 76.5%  
Earnings per share (Unadj.) Rs10.435.0 29.6%  
Cash flow per share (Unadj.) Rs16.349.4 32.9%  
Dividends per share (Unadj.) Rs03.00 0.0%  
Dividend yield (eoy) %00.4 0.0%  
Book value per share (Unadj.) Rs98.8247.1 40.0%  
Shares outstanding (eoy) m25.00126.35 19.8%   
Bonus/Rights/Conversions -ESOS-  
Price / Sales ratio x4.72.7 173.1%   
Avg P/E ratio x104.223.3 447.1%  
P/CF ratio (eoy) x66.416.5 402.5%  
Price / Book Value ratio x10.93.3 331.2%  
Dividend payout %08.6 0.0%   
Avg Mkt Cap Rs m27,008103,108 26.2%   
No. of employees `0001.413.4 10.1%   
Total wages/salary Rs m1,5357,874 19.5%   
Avg. sales/employee Rs Th4,210.92,807.0 150.0%   
Avg. wages/employee Rs Th1,132.2585.8 193.3%   
Avg. net profit/employee Rs Th191.1329.0 58.1%   
INCOME DATA
Net Sales Rs m5,71037,732 15.1%  
Other income Rs m123577 21.2%   
Total revenues Rs m5,83338,309 15.2%   
Gross profit Rs m4636,901 6.7%  
Depreciation Rs m1471,824 8.1%   
Interest Rs m0189 0.0%   
Profit before tax Rs m4385,465 8.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1791,042 17.2%   
Profit after tax Rs m2594,422 5.9%  
Gross profit margin %8.118.3 44.3%  
Effective tax rate %40.819.1 214.1%   
Net profit margin %4.511.7 38.7%  
BALANCE SHEET DATA
Current assets Rs m3,20923,778 13.5%   
Current liabilities Rs m2,07010,975 18.9%   
Net working cap to sales %20.033.9 58.8%  
Current ratio x1.62.2 71.6%  
Inventory Days Days72104 69.7%  
Debtors Days Days3566 53.0%  
Net fixed assets Rs m79020,368 3.9%   
Share capital Rs m50253 19.8%   
"Free" reserves Rs m2,41930,971 7.8%   
Net worth Rs m2,46931,224 7.9%   
Long term debt Rs m01,409 0.0%   
Total assets Rs m4,60545,507 10.1%  
Interest coverage xNM30.0-  
Debt to equity ratio x00 0.0%  
Sales to assets ratio x1.20.8 149.5%   
Return on assets %5.610.1 55.5%  
Return on equity %10.514.2 74.1%  
Return on capital %17.717.3 102.4%  
Exports to sales %045.9 0.0%   
Imports to sales %016.6 0.0%   
Exports (fob) Rs mNA17,308 0.0%   
Imports (cif) Rs mNA6,266 0.0%   
Fx inflow Rs m30017,308 1.7%   
Fx outflow Rs m2,0156,266 32.2%   
Net fx Rs m-1,71511,042 -15.5%   
CASH FLOW
From Operations Rs m884,923 1.8%  
From Investments Rs m-94-1,563 6.0%  
From Financial Activity Rs mNA-1,832 0.0%  
Net Cashflow Rs m-61,528 -0.4%  

Share Holding

Indian Promoters % 0.0 45.9 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 0.3 11.4 2.6%  
FIIs % 15.7 25.3 62.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 17.4 52.3%  
Shareholders   12,856 36,892 34.8%  
Pledged promoter(s) holding % 0.0 2.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   SHASUN PHARMA  DR. REDDYS LAB  ABBOTT INDIA  UNICHEM LAB  WYETH LTD  

Compare ASTRAZENECA PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices End Flat; Power and Telecom Stocks Witness Buying(Closing)

Indian share markets witnessed volatile trading activity throughout the day today and ended on a flat note.

Related Views on News

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY20); Net Profit Down 2.5% (Quarterly Result Update)

May 20, 2020 | Updated on May 20, 2020

For the quarter ended March 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 96 m (down 2.5% YoY). Sales on the other hand came in at Rs 2 bn (up 2.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

IPCA LABS Announces Quarterly Results (3QFY20); Net Profit Up 22.8% (Quarterly Result Update)

Feb 17, 2020 | Updated on Feb 17, 2020

For the quarter ended December 2019, IPCA LABS has posted a net profit of Rs 2 bn (up 22.8% YoY). Sales on the other hand came in at Rs 11 bn (up 20.2% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (2QFY20); Net Profit Up 63.7% (Quarterly Result Update)

Nov 12, 2019 | Updated on Nov 12, 2019

For the quarter ended September 2019, IPCA LABS has posted a net profit of Rs 2 bn (up 63.7% YoY). Sales on the other hand came in at Rs 12 bn (up 21.5% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (1QFY20); Net Profit Up 101.5% (Quarterly Result Update)

Aug 27, 2019 | Updated on Aug 27, 2019

For the quarter ended June 2019, IPCA LABS has posted a net profit of Rs 1 bn (up 101.5% YoY). Sales on the other hand came in at Rs 10 bn (up 18.4% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 236.5% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 215 m (up 236.5% YoY). Sales on the other hand came in at Rs 2 bn (up 26.7% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

More Views on News

Most Popular

These 5 Smallcaps Deserve a Place in Your Coffee Can Portfolio(Profit Hunter)

Jul 28, 2020

When it comes to quality stocks, doing less is more.

Before You Buy Your First Electric Vehicle Consider Buying this Stock(Profit Hunter)

Jul 29, 2020

As competition intensifies in the electric vehicle space, only few will create huge wealth over the years.

How to Buy Gold and Silver(Fast Profits Daily)

Jul 27, 2020

In this video I'll show you how to buy bullion the right way.

Elon Musk Gives Us a Trading Opportunity(Fast Profits Daily)

Jul 28, 2020

Elon Musk made a statement recently which I believe, gives us a fast profit trading opportunity.

More

Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Aug 7, 2020 (Close)

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA - LUPIN COMPARISON

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS